Dublin, Ireland-based lipid science group DS Biopharma has launched a spin-out group focused solely on fibrotic conditions such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders such as chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF).
The new company, called Afimmune, will continue explore the potential of DS102, a novel, anti-fibrotic compound, in NASH as well as certain pulmonary disorders, and also has a number of other compounds in preclinical development.
Afimmune plans to start a Phase IIa study with DS102 in NASH patients later this year, as well as a Phase IIa clinical trial in COPD patients following positive preclinical data.
DS Biopharma will concentrate its efforts on the development of DS107, an anti-inflammatory compound for atopic dermatitis and pruritus, and DS109 for other inflammatory skin disorders such as acne.
“By spinning out DS102 into a new company, DS Biopharma can direct its full attention to developing products for inflammatory skin conditions whereas Afimmune will focus on fibrotic conditions and pulmonary disorders,” noted Dr John Climax, the firm’s executive chairman.
By Selina McKee
Source: Pharma Times
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
